Novo Nordisk is the global leader in diabetes and obesity care, pioneering GLP-1 therapies such as semaglutide. It funds extensive metabolic-disease research through the Novo Nordisk Foundation and collaborates with Danish and international universities on protein engineering.
R&D SPEND
$5.2B
INDUSTRY
Biopharma
290
ACADEMIC COLLABORATIONS
14000
PATENTS
TRY IT
Install the CLI and run your first search in under a minute. No account required to explore.
npx sci-buy@latest COPIED